Clyburn Frank 4

What Happened

• Frank Clyburn, a director of Revolution Medicines (RVMD), was granted awards on 2026-06-18: 1,191 shares reported as acquired at $0.00 and a 3,127-share derivative award reported as acquired at $0.00. The reported grants have no purchase price (they were awards/compensation grants), so no cash changed hands for the awards themselves.

Key Details

• Transaction date: 2026-06-18; Form 4 filed: 2026-06-23 (five days after the transaction).
• Reported grant entries: 1,191 shares @ $0.00 (acquired) and 3,127 shares @ $0.00 (derivative, acquired).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes from the filing:
  • F1: Includes 4,080 restricted stock units.
  • F2: The shares subject to the option will vest in full on the earlier of (i) the first anniversary of June 18, 2026, or (ii) immediately prior to the Annual Meeting following the grant date, subject to continued service.
• Filing timeliness: The Form 4 was filed five days after the reported transaction date, which exceeds the typical 2-business-day reporting requirement for insiders.

Context

• These were awards/grants (transaction code A) — not open-market purchases or sales — and are typically part of director compensation rather than a direct market-positioning trade.
• The 3,127-share line is recorded as a "derivative" award; footnote F2 describes a simple vesting schedule (no immediate sale or cashless exercise reported).
• Awards and RSUs do not necessarily indicate buying/selling sentiment by the insider; they reflect compensation and future vesting conditions.